| Species |
Human |
| Protein Construction |
MRC2 (Gly31-Pro530)_x000D_
Accession # Q9UBG0 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1 EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
57.64 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
MRC2 (Mannose Receptor C Type 2) is a constitutively recycling endocytic receptor belonging to the mannose receptor family, which has been found to be closely involved with cancer metastasis. MRC2 expresses an extracellular fibronectin type II domain that binds to and internalizes collagen, suggesting that it may play a role in modulating renal fibrosis. |
| Synonyms |
C-type lectin domain family 13 member E, Endocytic receptor 180, Macrophage mannose receptor 2, Urokinase-type plasminogen activator receptor-associated protein (UPAR-associated protein; Urokinase receptor-associated protein) |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
